Health Catalyst, Inc. (NASDAQ:HCAT – Get Free Report) General Counsel Benjamin Landry sold 70,000 shares of the business’s stock in a transaction on Wednesday, November 11th. The stock was sold at an average price of $1.43, for a total transaction of $100,100.00. Following the completion of the sale, the general counsel directly owned 281,372 shares of the company’s stock, valued at $402,361.96. This represents a 19.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.
Benjamin Landry also recently made the following trade(s):
- On Thursday, November 12th, Benjamin Landry sold 29,478 shares of Health Catalyst stock. The shares were sold at an average price of $1.39, for a total value of $40,974.42.
Health Catalyst Trading Up 11.0%
Shares of NASDAQ:HCAT traded up $0.15 on Friday, reaching $1.51. 465,291 shares of the company traded hands, compared to its average volume of 348,183. The stock has a market capitalization of $114.99 million, a P/E ratio of -0.53 and a beta of 1.52. The business’s 50-day simple moving average is $1.69 and its 200 day simple moving average is $1.68. Health Catalyst, Inc. has a 52 week low of $0.96 and a 52 week high of $3.02.
Wall Street Analyst Weigh In
HCAT has been the subject of a number of recent analyst reports. Citigroup lowered their price target on shares of Health Catalyst from $2.50 to $2.00 and set a “neutral” rating for the company in a report on Tuesday, August 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Health Catalyst in a research report on Monday, October 26th. Canaccord Genuity Group lowered shares of Health Catalyst from a “buy” rating to a “hold” rating and cut their price target for the stock from $3.00 to $1.80 in a report on Thursday, August 20th. Finally, Wells Fargo & Company cut their price target on shares of Health Catalyst from $1.75 to $1.50 and set an “equal weight” rating on the stock in a report on Thursday, August 13th. Five investment analysts have rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Reduce” and an average price target of $2.01.
Read Our Latest Analysis on Health Catalyst
Institutional Trading of Health Catalyst
Large investors have recently bought and sold shares of the company. Palogic Value Management L.P. bought a new position in shares of Health Catalyst in the 2nd quarter worth approximately $9,796,000. BlackRock Inc. bought a new stake in shares of Health Catalyst during the second quarter valued at approximately $3,654,000. Marshall Wace LLP bought a new stake in shares of Health Catalyst during the third quarter valued at approximately $1,810,000. Hsbc Holdings PLC bought a new stake in shares of Health Catalyst during the second quarter valued at approximately $809,000. Finally, Squarepoint Ops LLC boosted its position in shares of Health Catalyst by 1,214.8% during the second quarter. Squarepoint Ops LLC now owns 400,210 shares of the company’s stock valued at $796,000 after purchasing an additional 369,772 shares in the last quarter. 85.00% of the stock is owned by institutional investors.
Health Catalyst Company Profile
Health Catalyst, Inc. provides data and analytics technology and services to healthcare organizations. Its solutions are designed to help providers use clinical, operational, and financial data to support decision-making and improve care delivery. The company’s offerings include a data platform that brings together information from multiple sources, analytics applications for healthcare workflows, and professional services. These services can include implementation, data management, and support for organizations developing and applying analytics programs.
Read More
- Five stocks we like better than Health Catalyst
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Health Catalyst Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Health Catalyst and related companies with MarketBeat.com's FREE daily email newsletter.
